PF-Atlas › Clinical Trials › NCT04105972

A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del

ELX/TEZ/IVA · Phase 3

Registry ID
NCT04105972
Phase
Phase 3
Status
Completed
Drug / intervention
ELX/TEZ/IVA
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2019-10-03
Enrollment
176
Locations
35

About this trial

This study will evaluate the efficacy, safety, and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous for F508del.

View NCT04105972 on ClinicalTrials.gov →

Explore related

All ELX/TEZ/IVA trialsAll IPF trials

Related trials

ELX/TEZ/IVA — NCT05153317ELX/TEZ/IVA — NCT04545515ELX/TEZ/IVA — NCT05274269ELX/TEZ/IVA — NCT03691779ELX/TEZ/IVA — NCT04702360ELX/TEZ/IVA — NCT04362761
Medical disclaimer. This page summarizes public trial data for NCT04105972 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.